What is Glucagon?
Glucagon is a hormone medicine used to raise dangerously low blood glucose. It serves a different role from medicines aimed at lowering glucose or weight.
Biological role or research focus
Release of stored glucose.
Emergency treatment of severe hypoglycemia is a distinct use from metabolic weight-management research.
Role reference: MedlinePlus · Glucagon ↗
- Class / identity
- Glucose-raising hormone
- Main research area
- Severe hypoglycemia rescue
- Evidence featured
- Human randomized crossover trial
- Source check
- October 4, 2026
Source: MedlinePlus · Glucagon ↗
Quick answers
- Is Glucagon FDA approved?
- Yes. Gvoke (NDA 212097), Baqsimi nasal powder (NDA 210134) and glucagon for injection (e.g., NDA 201849) for severe hypoglycemia. Source ↗
- Is Glucagon safe?
- Approved hormone for severe low blood sugar and as a diagnostic aid; generally well tolerated, but dangerous in people with pheochromocytoma or insulinoma. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Glucagon banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Nasal versus intramuscular glucagon (2016) | Human randomized crossover trial | 75 adults with type 1 diabetes under supervised experimental hypoglycemia. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized crossover trial · 2016
Nasal versus intramuscular glucagon
Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.
- Population / model
- 75 adults with type 1 diabetes under supervised experimental hypoglycemia.
- Study design
- Each participant received the two formulations on separate study visits; glucose recovery was assessed within 30 minutes.
- Main finding
- Success occurred in 98.7% of nasal visits versus 100% of intramuscular visits. Mean recovery times were 16 and 13 minutes, respectively.
- Limits & context
- This was a controlled rescue-treatment study, not a comparison of unsupervised use in every emergency. The nasal and injected products have different delivery systems.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
15 registered studies name Glucagon as an intervention among the 100 most recently updated of 1541 search results; 8 are recruiting or under way, 3 have not started recruiting yet, 3 completed and 1 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 15 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Hepatic glucagon action: beyond glucose mobilization. ↗
Physiological reviews · 2024 Jul 1 · Journal Article, Review, Research Support, Non-U.S. Gov't
100 years of glucagon and 100 more. ↗
Diabetologia · 2023 Aug · Journal Article, Review, Research Support, Non-U.S. Gov't
Read available full text ↗
The past, present, and future physiology and pharmacology of glucagon. ↗
Cell metabolism · 2022 Nov 1 · Journal Article, Review, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural
Read available full text ↗
A famsin-glucagon axis mediates glucose homeostasis. ↗
Cell metabolism · 2025 Mar 4 · Journal Article
Risks & interactions
Approved hormone for severe low blood sugar and as a diagnostic aid; generally well tolerated, but dangerous in people with pheochromocytoma or insulinoma.
This entry follows the Gvoke VialDx label, which also covers Gvoke. Safety comes from controlled trials in adults and children plus postmarketing reports across glucagon products.
Take extra care with: Heart or blood pressure problemsBlood thinners or bleeding problemsDiabetes or blood-sugar medicines
From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
- People with pheochromocytoma (risk of a sharp rise in blood pressure)
- People with insulinoma (risk of low blood sugar)
- Past allergic reaction to glucagon or any ingredient
- People with glucagonoma, when used as a diagnostic aid
Interactions
- Beta-blockers: temporary rise in pulse and blood pressure
- Indomethacin: glucagon may fail to raise blood sugar or may even lower it
- Warfarin: stronger blood-thinning effect, with more bruising or bleeding
- Anticholinergic drugs: more gut side effects during diagnostic use
- Insulin: works against glucagon, so blood sugar needs monitoring
Serious risks
- Sharp blood pressure rise in undiagnosed pheochromocytoma
- Low blood sugar in people with insulinoma or glucagonoma
- Serious allergic reactions, including anaphylactic shock
- May not work with low liver glycogen stores, such as starvation, adrenal insufficiency or chronic low blood sugar
- A skin rash (necrolytic migratory erythema) reported with prolonged continuous exposure
- Higher blood pressure and heart rate in heart disease, and high blood sugar in diabetes, during diagnostic use
Common side effects
- nausea
- vomiting
- injection-site swelling
- headache
- low blood sugar (in children)
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Gvoke VialDx (glucagon) prescribing information ↗
Key precautions
Nausea and vomiting can occur. Pheochromocytoma, insulinoma, and other relevant conditions require product-specific review. A rescue product’s instructions and emergency-care plan matter more than a generic peptide description.
Source: MedlinePlus · Glucagon ↗
Regulatory status
- U.S. FDA approval
- Approved
Gvoke (NDA 212097), Baqsimi nasal powder (NDA 210134) and glucagon for injection (e.g., NDA 201849) for severe hypoglycemia; also used as a diagnostic aid. Older Lilly and Novo (GlucaGen) applications are listed as discontinued. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Clinical uses & product context
Approved preparations support emergency treatment of severe hypoglycemia; some injectable products also have diagnostic uses. The linked trial compares nasal and intramuscular rescue formulations.
Source: MedlinePlus · Glucagon ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.
Mechanism & research rationale
It prompts the liver to release stored glucose. Certain diagnostic uses also take advantage of its effects on digestive-muscle movement.
Source: MedlinePlus · Glucagon ↗
Molecular structure
Questions worth asking
- Which indication and formulation does the source describe?
- Does the video make a broader claim than the source supports?
- Emergency treatment of severe hypoglycemia is a distinct use from metabolic weight-management research.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Why can glucagon raise glucose while GLP-1 medicines lower it?
They are different hormones with different targets. Similar naming does not imply the same physiological role.
Source: MedlinePlus · Glucagon ↗
Did the nasal study involve real-world unconscious emergencies?
It used supervised insulin-induced hypoglycemia. That controlled setting is an important limitation when interpreting the result.
References & editorial record
- MedlinePlus · Glucagon ↗
- Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
